Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics Inc (BNGO) delivers cutting-edge optical genome mapping solutions for advanced genomic research. This news hub provides investors and researchers with essential updates on the company's innovations in structural variation analysis.
Access official press releases, financial disclosures, and technology developments in one centralized location. Track updates spanning product launches, clinical study collaborations, and peer-reviewed research validations of Bionano's OGM platform. Our curated collection ensures timely access to material developments impacting the genome analysis sector.
Key focus areas include regulatory milestones, partnership announcements, and scientific advancements demonstrating Bionano's leadership in next-generation cytogenetics. All content maintains strict factual accuracy required for informed investment decisions and research applications.
Bookmark this page for streamlined monitoring of Bionano's progress in transforming genomic medicine through high-resolution genome analysis tools. Verify critical updates directly from primary sources with our comprehensive news aggregation.
Bionano Genomics (BNGO) announced its inaugural Strategy Day on February 2, 2023, at the Nasdaq MarketSite in New York City, starting at 1:30 PM ET. The event will showcase presentations from the leadership team and discussions with key opinion leaders in cancer and genetic disorders. A Q&A session will follow, allowing audience interaction. A live webcast will be available for registration through the company's website. Bionano focuses on genome analysis solutions, enhancing research in biology and medicine.
Bionano Genomics (BNGO) reported preliminary financial highlights for Q4 and full year 2022, expecting revenues between $8.1 million and $8.4 million, marking a 29% to 33% increase year-over-year. The installed base of Saphyr systems reached 240, a 46% jump from 2021. Overall, 2022 revenues are estimated at $27.7 million to $28 million, representing a 54% to 56% increase. The company achieved all its 2022 milestones, including launching new OGM laboratory tests and enhancing its DNA sample preparation workflow.
Bionano Genomics (BNGO) announced a peer-reviewed study recommending optical genome mapping (OGM) as a first-line analysis for acute myeloid leukemia (AML). Conducted by eight research institutes, the study found OGM to be superior and more cost-effective than traditional methods like karyotyping. Key findings included a 100% concordance with these methods, and OGM identified pathogenic variants in 12% of cases, which could alter risk levels or clinical trial eligibility. The results support OGM's potential as a standard of care for cytogenomic evaluation in AML.
Bionano Genomics (Nasdaq: BNGO) announced its participation in the ASH Annual Meeting from December 10-13, 2022, in New Orleans, Louisiana. The event will showcase the potential of optical genome mapping (OGM) technology in myeloid cancer and hematological research. Notable presentations include a workshop led by Dr. Rashmi Kanagal-Shamanna and four scientific posters focused on OGM applications in major blood disorders. The company’s CEO expressed enthusiasm about the growing adoption of OGM among researchers.
Bionano Genomics, Inc. (NASDAQ: BNGO) has announced a definitive agreement to acquire Purigen Biosystems, Inc. for up to $64 million. This acquisition includes the Ionic® Purification System and proprietary isotachophoresis (ITP) technology for improved nucleic acid isolation and purification, aimed at enhancing the optical genome mapping (OGM) process. The transaction is anticipated to close by December 8, 2022. Bionano expects the integration of Purigen's technology to simplify workflows and expand its sample prep capabilities, potentially accelerating OGM adoption in various research areas.
Bionano Genomics has appointed Donna Polizio as its global head of market access, enhancing its leadership team. Polizio, previously a vice president at Genomic Health, will focus on promoting optical genome mapping (OGM) adoption and securing reimbursement for OGM-based tests, particularly in the U.S. She brings extensive experience in diagnostics and reimbursement strategies. Bionano's CEO, Erik Holmlin, expressed confidence that Polizio's expertise will aid in advancing the company's goals, particularly in achieving better reimbursement pathways for OGM diagnostics.
Bionano Genomics (BNGO) reported impressive Q3 2022 results, achieving 55% year-over-year revenue growth to $7.2 million, the highest in company history. The installed base of Saphyr systems grew to 217, marking an 11% increase from Q2 2022. The company increased cash reserves to $180.2 million and remains on track to meet its ELEVATE! milestones. Gross margin improved to 25% due to enhanced production yields. The fourth-quarter revenue guidance is set between $7.5 million and $8 million. A dedicated session on genome mapping at ASHG reflects OGM's rising prominence.
Bionano Genomics (Nasdaq: BNGO) released a validation study showcasing the effectiveness of optical genome mapping (OGM) compared to traditional cytogenetic methods in analyzing hematological neoplasms. The study involved 69 samples and revealed a 100% first-pass rate for OGM, with a sensitivity of 98.7%, specificity of 100%, and accuracy of 99.2%. OGM also identified additional structural variants, aiding better tumor classification and therapy selection. CEO Erik Holmlin expressed optimism about OGM’s potential as a primary cytogenomic test for hematologic malignancies.
Bionano Genomics (Nasdaq: BNGO) will participate in the Association for Molecular Pathology (AMP) Annual Meeting and Expo 2022, showcasing optical genome mapping's (OGM) applications, including genetic disease and hematological malignancies. Key presentations include workshops on enhancing detection of pathogenic structural variants, and methodologies for homologous recombination deficiency assessment. The event will highlight OGM's integration with next-generation sequencing. The conference runs from November 1-5, 2022, in Phoenix, Arizona, underscoring OGM's growing recognition in molecular pathology.
Bionano Genomics (BNGO) will host a conference call and live webcast on November 3, 2022, at 4:30 p.m. ET to discuss its Q3 2022 financial results and corporate advancements. Investors can participate via a toll-free number or through a dedicated webcast link. The call will be accessible for replay on Bionano's investor relations website for 30 days following the event. Bionano Genomics focuses on genome analysis solutions, aiming to enhance diagnostics through its various platforms, including Lineagen and BioDiscovery.
